Kimberly Hicks 8/13/25 Kimberly Hicks 8/13/25

argenx Delivers Strong First Half Performance!

Read More

Kimberly Hicks 8/11/25 Kimberly Hicks 8/11/25

Alnylam Pharmaceuticals continues to lead in RNAi therapeutics with a standout quarter!

Read More

Kimberly Hicks 8/5/25 Kimberly Hicks 8/5/25

Apellis Pharmaceuticals receives FDA approval of EMPAVELI® (pegcetacoplan)

Read More

Kimberly Hicks 5/20/25 Kimberly Hicks 5/20/25

argenx Kicks Off 2025 with Record-Breaking Growth

Read More

Kimberly Hicks 5/10/25 Kimberly Hicks 5/10/25

Big Moves in AI-Driven Oncology: Pathos Secures Major Backing

Read More

Kimberly Hicks 5/9/25 Kimberly Hicks 5/9/25

Another strong quarter for our client Alnylam Pharmaceuticals

Read More

Kimberly Hicks 3/24/25 Kimberly Hicks 3/24/25

Pathos has officially dosed the first patient in its Phase 1b/2a clinical trial evaluating Pocenbrodib.

Read More

Kimberly Hicks 3/21/25 Kimberly Hicks 3/21/25

Congratulations to Alnylam Pharmaceuticals on the FDA Approval of Amvuttra.

Read More

Kimberly Hicks 2/19/25 Kimberly Hicks 2/19/25

Dewpoint Therapeutics succeeds in the nomination of DPTX3496 as their second development candidate!

Read More